---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-030773"
form_type: "8-K"
ticker: "NVCT"
cik: "0001875558"
company_name: "Nuvectis Pharma, Inc."
filed_at: "2024-03-05T23:59:59+00:00"
generated_at: "2026-06-05T04:13:02.470239+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Nuvectis Pharma FY2023 net loss $22.3M; cash $19.1M; NXP800 data update expected March 2024

## Summary
- Cash and cash equivalents $19.1M at Dec 31, 2023, down from $20.0M at Dec 31, 2022.
- Net loss for FY2023 was $22.3M vs $19.1M in FY2022; includes $4.7M non-cash stock compensation.
- R&D expenses increased to $15.4M from $13.2M; G&A increased to $7.5M from $6.0M.
- NXP800 Phase 1b preliminary data update expected in March 2024 for platinum-resistant ARID1a-mutated ovarian cancer.
- NXP900 Phase 1a dose escalation initiated; multiple clinical data readouts expected in 2024.

## SEC filing metadata
- accession: 0001104659-24-030773
- form_type: 8-K
- ticker: NVCT
- cik: 0001875558
- company_name: Nuvectis Pharma, Inc.
- filed_at: 2024-03-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1875558/000110465924030773/0001104659-24-030773-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1875558/000110465924030773/tm247868d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-030773
- JSON: https://secwatch.observer/filing/0001104659-24-030773.json
- Plain text: https://secwatch.observer/filing/0001104659-24-030773.txt

## Key facts
- Earnings Releases
  Nuvectis Pharma, Inc. reported the fiscal year ended December 31, 2023 results: net income $22.3 million.
  - Period: the fiscal year ended December 31, 2023
  - Net income: $22.3 million
  - Result: reported results
  source text: The Company's net loss was $22.3 million for the year ended December 31, 2023, compared to $19.1 million for the year ended December 31, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1875558/000110465924030773/0001104659-24-030773-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.